This round is no longer accepting investments, but hundreds just like it are live now.

Log In


Utilizing Gene Repair Therapy to Treat Diseases

PhorMed is a Biotech Company paving the way in the advancement of a Gene Repair Therapy with our lead drug internally called RP-323. Our drug has the ability to repair cells allowing the body to recover. We are looking to treat a variety of disorders such as Parkinson’s disease, Acute Myeloid Leukemia, Hodgkin’s Lymphoma and Acute Respiratory Distress Syndrome, caused by COVID-19

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

$240,443 Raised

Reasons to Invest

  • Our goal is to replace CHEMOTHERAPY treatment with an ALTERNATIVE TREATMENT that, if we make it to market, would NOT REQUIRE HOSPITAL STAYS in most cases.

  • Our drug can potentially treat multiple diseases resulting in a greater chance of success and larger market potential, a combined overall market potential of over $12 billion per year.

  • We have a highly credentialed team. Our key personnel and advisory board members have compiled a combined 565 peer reviewed publications and abstracts. PhorMed has raised over $2.5 million and gained more than 4,100 total shareholders, and 8,800+ followers.


Discovering new approaches to therapy in the field of Genomic Medicine

PhorMed is a clinical stage biopharmaceutical company, utilizing Gene Repair Therapy to develop our drug RP-323, to treat diseases such as Parkinson’s disease, Acute Myeloid Leukemia, Hodgkin’s Lymphoma and ARDS, caused by COVID-19. PhorMed is pre-revenue and does not currently have a product on the market.

A number of indications are under development which are all categorized as inflammatory disorders. It has been determined that RP-323 is active along specific cell lines, being able to target damaged or mutated cells due to cancer, viruses, and a variety of other factors.

Our studies include cancer cells, blood cells, and, as a result of its special ability to pass through the Blood Brain Barrier (BBB), neurological cells. Because of RP-323’s wide range of activity, the company has been able to build a broad platform from a single molecule. 

The company is working on a treatment for Parkinson’s disease that we believe is in line to become one of the top innovative therapies. RP-323 is also targeted to be a first-line treatment in Oncology, Neurology, and Anti-Virus. The company’s mission is to treat unmet medical needs by treating the cause, and in some cases, the symptom. 

This is accomplished through differentiation, RP-323’s ability to repair the DNA of damaged or mutated cells; immunotherapy, boosting the body’s immune system through cytokine induction; and by stem cell signaling and proliferation, stimulating cell division once the cell is repaired and functioning properly. All of these mechanisms work in unison allowing the body to heal and return to a healthy condition.

Five indications are presently in the pipeline and the company will continue to expand through its continued dedication in research and development. We are committed to the highest standards of scientific excellence and integrity to accomplish these goals for our patients and society. 

the problem

Problematic CHEMOTHERAPY as a treatment or at times NO AVAILABLE OPTIONS

Patient options are frequently limited and at times no known effective options are available.  

With patients suffering from Acute Myeloid Leukemia (AML) or Hodgkin’s Lymphoma (HL), chemotherapy has been the traditional option which is well known to have harmful or lethal side effects, while those with Parkinson’s disease (PD) and Acute Respiratory Distress Syndrome (ARDS), caused by COVID-19 are faced with no realistic treatment options. PhorMed is attempting to offer NEW FIRST-LINE TREATMENTS in these areas allowing patients new hope. (source, source, source, source)

the solution

Our goal is to REPLACE CHEMOTHERAPY in selected Oncology markets and offer new options for all diseases we are attempting to treat

We are looking to offer new treatments for AML, HL, PD, and ARDS caused by COVID-19. Our goal is to make faster acting treatments that are safer for patients, and to make chemotherapy obsolete in our selected markets.

We focus on treating diseases through Gene Repair Therapy

RP-323 utilizes Gene Repair Therapy to target damaged or mutated cells and repair a broad range of cell types. Our technology focuses on the root cause, aiming to fix the cellular damage on a molecular level. 


The drug will be administered through intravenous infusion.

THE Market

These deadly diseases are widespread

The world market for drugs treating HL is projected to post a compound annual growth rate (CAGR) of 14.75% for the forecast period of 2022-2026.  The same projections expect the market to reach $1.85 billion by 2026.


The CAGR of the AML market is expected to be around 14% over the next five years, and is expected to top $2.22 billion by 2026.


The PD world drug market is expected to reach $8.38 billion at CAGR of 8.1% by 2026.

Combined, the total annual market for three of our drug's potential uses could reach close to $12.45 billion by 2026.


The COVID-19 market is still to be determined. 

Initial studies have shown our treatments are non-toxic with limited side effects.  

Chemotherapy has long-lasting and potentially devastating side effects and can severely damage and kill healthy cells. 


Depending on the severity of a disease when our drug is administered, a majority of treatment recipients will not be required to have hospital stays thanks to the limited side effects and unobtrusive nature of the drug. We believe our treatment will be a safer and non-toxic alternative for a variety of applications including cancer, viruses and neurological disorders. 


Our drug has been proven to be safe by the FDA in early studies

Our drug has been found to be safe for use in humans after the completion of the Phase 1 study. We are allocating a large majority of our funds towards clinical research and are actively proceeding with next steps in clinical research for all our indications. 

RP-323 originally conducted a Phase I trial in 2004-2005. For human FDA trials, there are only three phases prior to entering into the marketplace. Those are Phase 1, Phase 2, Phase 3. Once Phase 1 is complete, the FDA may require an abbreviated safety phase to be included within the Phase 2 study which they call phase 1/2 or I/II. The 1 (I) portion of 1/2 (I/II) is an abbreviated safety step. Once the abbreviated safety step is completed companies move directly to starting Phase 2 (II). As of 2022, PhorMed is currently in phase 1/2 (I/II). We are not currently active in a trial at this time however we are in preparation for this next phase.


With your help and proper funding, we expect to eventually complete Phase 2 in all our clinical trials and move into the last stages of testing and finally into the hands of patients who need better options. 

Why invest

Help us modernize the medical industry by making medicine safer and less costly

We are driven to replace Chemotherapy as a first-line treatment offering doctors and patients better options.

We are looking to offer patients a safe and effective way to better health and treatment methods with fewer side effects. We strive to make medical treatment less costly and available to all by reducing or eliminating the need for hospital stays. 

We have an opportunity to improve the path patients take to recovery. With your help, we can make chemotherapy a thing of the past.


We believe our technology is the future of medicine. With your financial support we can pave the way to a healthier future with lower medical costs by eliminating or reducing the need for hospital stays, and moving medicine forward into modern times.


1999 Avenue of the Stars, #1100
Century City, CA 90067

PhorMed is a Biotech Company paving the way in the advancement of a Gene Repair Therapy with our lead drug internally called RP-323. Our drug has the ability to repair cells allowing the body to recover. We are looking to treat a variety of disorders such as Parkinson’s disease, Acute Myeloid Leukemia, Hodgkin’s Lymphoma and Acute Respiratory Distress Syndrome, caused by COVID-19


Prof. Richard L. Chang

Prof. Richard L. Chang

Inventor and CSO

• 53+ years of research experience

• Inventor and holder of multiple patents

• 124 peer-reviewed journal publications

• 150+ Scientific Abstracts

• Holder of 9 Patents

Professor Chang has filed multiple significant patents for the treatment of cancer, infectious disease, hematology, and neurological disorders. Prof. Chang has over 53 years of research experience with such companies as Hoffman-La-Roche, Schering Corp, and Burroughs Wellcome and is a full professor and director of Research at Rutgers University. He successfully launched and completed off IND and IND phase I trials in China and US.

Ben Chang

Ben Chang

CEO, CFO, President, Director

• 29+ years experience in multiple biotech and pharmaceutical business ventures

• 16+ years of executive level experience in Biotech business ventures

• Holder of 2 patents

Mr. Chang has previously been founder, director, CEO, President, CFO, and/or COO of such biotech companies as Biosuccess Biotech Co. LTD., Rich Pharmaceuticals, Inc., and HypGen, Inc. Mr. Chang started his life-science career as the founder and managing partner of Sun-Rich Chemicals, product development and distribution organization for nutraceuticals. Mr. Chang also has experience in international banking, venture capital, M&A, finance, go-public transactions, and organizational design and operations. Mr. Chang has a Bachelor of Science Degree in Economics from East Carolina University where he focused on accounting and international business.

Carole A. Salvador, Psy.D.

Carole A. Salvador, Psy.D.

HR Director/Secretary/Treasurer

Dr. Salvador created and manages a Clinical, Coaching and Organizational Consulting practice, Affiliates in Psychology and Education for over 30 years. She was a principal in the organizational consulting firm of Cogent Resources and has experience in management, business and scientific research experience and psychopharmacology expertise. Prior to her career in Applied Psychology, she worked in Biochemistry research at Cornell Medical School and Pharmacology research at Burroughs Welcome which is now part of GSK. Dr. Salvador received her Doctor of Psychology from Rutgers University in Applied Psychology and a B.S. in the Biological Sciences from New York University. She has expertise and holds a certificate in psychopharmacology, completed a post-doctoral fellowship in Community Systems and a post-doctoral program in Organizational Development and Consultation at the William Alanson White Institute.

Sean M. O’Connell, Ph.D

Sean M. O’Connell, Ph.D

Chief Medical Officer

• 36+ years experience in Immunology, Cell Biology, Regenerative Medicine, and Tissue Repair

• 65+ peer reviewed publications

Dr. O'Connell has served as CSO, CMO, Chief Scientist, SVP, and Founder of multiple pharmaceutical and research companies such as Novartis Pharmaceuticals, Vertical Spine, LLC., Cascade Medical Enterprises, and Integrated Communications Corp. (ICC/IPG). He has received numerous research grants and currently holds the position of Adjunct Professor in the Department of Vascular Surgery, Englewood Hospital and Medical Center, Mount Sinai School of Medicine, New York. He received his PhD in immunology and molecular biology from Rutgers University and the University of Medicine and Dentistry of New Jersey at New Brunswick (now Rutgers Medical school).

Stuart Greene

Stuart Greene

VP of Marketing & Business Development (Part-Time)

Mr. Greene has over 23 years experience in Business Development and Marketing, and extensive experience in C-Level Business Development. His experience includes direct B2B sales, Enterprise Software Sales, Business Development and Marketing, as well as IBM Power Systems Sales and management of server and cloud services teams. He has a comprehensive background in the creation and editing of direct marketing content and campaigns. Mr. Greene has a Bachelor of Arts degree in Communications from Muhlenberg College.

Steven J. Davis

Steven J. Davis

Legal Counsel 

Mr. Davis has over 30 Years experience in corporate and business law and Extensive knowledge of Business and Corporate law. His experience ranges from serving on the Board of Directors of Philter Labs, Inc., and on the Board of Directors and Audit, Compensation and Nominating Committees of Telanetix, Inc. Prior to starting his own practice, Mr. Davis served as General Counsel and an executive officer of Molecular Imaging Corporation, and as in-house counsel for Leap Wireless International, Inc. He also practiced in the Business and Corporate Group in the San Diego office of Luce, Forward, Hamilton & Scripps LLP (now Dentons), a full-service law firm with over 200 attorneys, where he advised both private and public clients. Mr. Davis is licensed to practice law in California, the District of Columbia, and Minnesota. He received his Juris Doctor, Cum Laude, from the University of San Diego, School of Law in 1992. He received his B.A. in Political Science, Cum Laude, from Arizona State University in 1988.

McCoy Moretz M.D.

McCoy Moretz M.D.

Former CEO

In loving memory to our dear friend and colleague


Aug 18, 2022
$10k - $2.15M
Common Stock
Common Stock

Maximum Number of Shares Offered subject to adjustment for bonus shares

*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.

Investment Incentives and Bonuses*


First Week

Invest within the first week and receive 20% bonus shares.

Second Week

Invest within the first two weeks and receive 15% bonus shares.

Third Week

Invest within the first three weeks and receive 10% bonus shares.

Fourth Week

Invest within the first four weeks and receive 5% bonus shares.


$1,000+ | 5% Bonus Shares

Invest $1,000+ to receive 5% bonus shares & access to our Investor Club which allows you to vote on drug names, and receive special investor updates.

$5,000+ | 10% Bonus Shares

Invest $5,000+ to receive 10% bonus shares & access to our Investor Club.

$10,000+ | 15% Bonus Shares

Invest $10,000+ to receive 15% bonus shares & access to our Investor Club.

*All perks occur when the offering is completed.

The 10% StartEngine Owners' Bonus

PhorMed, Inc. will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $1.00 / share, you will receive 110 shares of Common Stock, meaning you'll own 110 shares for $100. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and time of offering elapsed (if any). Eligible investors will also receive the Owner’s Bonus and the 10% Loyalty Bonus Perk for all previous Crowdfunding offering 1 investors on StartEngine in addition to the aforementioned bonus.

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments. Salary payments made to one’s self, a friend or relative. Any expense labeled “Travel and Entertainment”.


Owners bonus
Stack Owner's Bonus & Rewards!

Members get an extra 10% shares in addition to rewards below!


Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into PhorMed.



stanley Evans

4 months ago




Mutea Alnuzely

9 months ago

Hello Why you keep your investors in the dark I am not receiving any updates , and what is the this future- company is doing to come to light ?!



Stephen Lee

a year ago

Is there a timeline when PhorMed will go public?



James Pond

a year ago

At what valuation was this 700k investment made?



Maurice JELLAD

a year ago

You said “ “ PhorMed plans to continue its ARDS studies and, in parallel, to further advance its RP-323 human drug development platform by filing a Phase 2 IND application with the USFDA.” How come PHASE 2 ? Are you not supposed to apply for PHASE 1 clinical trial on humans first ⁉️ The preliminary test on mouse was promising. Ow you need to apply for phase 1, right ?



Kathy Oleszkowicz

a year ago

Love the latest results update! Awesome news from the ARDS study!



Aerica Ostrov

a year ago

Hi PhorMed Team. Based on your Phase one Trial of 2004-2005, it would appear that getting to the next step of Phase 1/2 has taken 15+ years. Could you give us insights into the protracted time frame?



Arghya Chatterjee

a year ago

Hi Ben, I have already invested in the previous fund raising campaign. Kindly make me correct if I am wrong , as per as I know targeted cell treatment is already available for Hodgkin’s Lymphoma (HL) in today's medical science. In that case how much acceptance your product will be?



Maurice JELLAD

a year ago

Basically the crowd is investing in financing Morphed early research. Good luck for that. This is going to take another 20 years. I wish investors to be patient and keep they hope and continue departing with their cash for the greater cause. VCs will come later on to secure the cake at commercial stage , when phase 3 is completed , and will Save the day.



Walter Hunziker

a year ago

In the link to the Phase 1 study, I did not find the results or conclusions drawn from the study. Could you explain the molecular details of how your compound works and why it can be used for the mentioned diseases? Calling drug administration by infusion „non-invasive“ is misleading. The Phase 1 study described in the link mentions 12-O-Tetradecanoylphorbol-13-acetate as the drug. This is a chemical and as such the therapy chemotherapy (as opposed to immunotherapy, gene therapy, etc). The Phase 1 study was initiated in 1999 - more then 20 years ago! Do you hold a patent, for what, when was it granted and when will it expire? I assume it is not a big hurdle for a generics drug company to produce 12-O-Tetradecanoylphorbol-13-acetate.




Cancel anytime before 48 hours before a rolling close or the offering end date.



We want you to succeed and get the most out of your money by offering rewards and memberships!


Your info is your info. We take pride in keeping it that way!


Invest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.


Get To Know Us

Our Team



Important Message

Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRASIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.

Investment opportunities posted and accessible through the site are of three types:

1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.

Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.
By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.

Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.

California Investors Only – Do Not Sell My Personal Information

(800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to

StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.

StartEngine Marketplace

The availability of company information does not indicate that the company has endorsed, supports, or otherwise participates with StartEngine.

None of the information displayed on or downloadable from (the 'Website') represents a recommendation, offer, or solicitation of an offer to buy or sell any security. It also does not constitute an offer to provide investment advice or service. StartEngine does not (1) make any recommendations or otherwise advise on the merits or advisability of a particular investment or transaction, or (2) assist in the determination of fair value of any security or investment, or (3) provide legal, tax, or transactional advisory services.

All investment opportunities are based on indicated interest from sellers and will need to be confirmed.

Investing in private company securities is not suitable for all investors. An investment in private company securities is highly speculative and involves a high degree of risk. It should only be considered a long-term investment. You must be prepared to withstand a total loss of your investment. Private company securities are also highly illiquid, and there is no guarantee that a market will develop for such securities. Each investment also carries its own specific risks, and you should complete your own independent due diligence regarding the investment. This includes obtaining additional information about the company, opinions, financial projections, and legal or other investment advice. Accordingly, investing in private company securities is appropriate only for those investors who can tolerate a high degree of risk and do not require a liquid investment.

StartEngine Marketplace (“SE Marketplace”) is a website operated by StartEngine Primary, LLC (“SE Primary”), a broker-dealer that is registered with the SEC and a member of FINRA and the SIPC. StartEngine Bulletin Board ("SE BB") is a bulletin board platform that advertises interest in shares of private companies that previously executed Reg CF or Reg A offerings. SE BB enables shareholders to communicate interest in potential sales of shares in private companies and investors to discover, review, and potentially invest in private companies. As a bulletin board platform, SE BB provides a venue for investors to access information about private company offerings and connect with potential sellers. SE BB is distinct and separate from StartEngine Secondary (“SE Secondary”), which is an SEC-registered Alternative Trading System (ATS) operated by SE Primary. SE Secondary facilitates the trading of securities by matching orders between buyers and sellers and facilitating executions of trades on the platform. While a security may be displayed on the bulletin board, these securities will be subject to certain restrictions which may prevent the ability to buy and sell these securities in a timely manner, if at all. Even if a security is qualified to be displayed on the bulletin board, there is no guarantee an active trading market for the securities will ever develop, or if developed, be maintained. You should assume that you may not be able to liquidate your investment for some time or be able to pledge these shares as collateral.